Worldwide Glucose Tolerance Test Market is expected to grow at a CAGR of 10.4% and reach USD 21,796.0 million by 2023

Obesity directly contributes to the risk for diabetes. According to 2016 WHO report, more than 1.9 billion adults, were overweight and of these over 650 million were obese. In North American and Europe rate of obesity is highest among lower-income population, who live in urban areas are littered with fast-food outlets. In the Asia-Pacific region, obesity is highly prevalent in urban residents and then in rural areas and urban slums. Obesity is caused due to diet imbalance, Genetics etc. are leading to various risk factors for diabetes, high blood pressure, heart disease and other health problems. Risk factors of diabetes and high blood pressure are increasing steadily with rise in prevalence of obesity. Thus the increasing prevalence of obesity globally, offers a great opportunity for the growth of the global glucose tolerance test market.

Taste the market data and market information presented through more than 128 market data tables and figures spread over 105 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Glucose Tolerance Test market research report–Global forecast till 2023.”

Get a sample report at https://www.marketresearchfuture.com/sample_request/4921 .

Major Players in the Glucose Tolerance Test Market

Some of the key players in the global market are Panasonic, Dexcom, Inc, Abbott Laboratories, F. Hoffman-La Roche Ltd, LifeScan, Inc Sanofi, Medtronic Plc and others.

Regional Analysis

Across the globe, health systems are developing in response to multiple factors such as new medical technology, new health services, changes in health policies, new organizational structures, innovations in drug development, and greater access to health services.

According to the WHO, Diabetes and its related complications lead to the substantial economic loss to diabetic people and to national economies through loss of work and wages, and direct medical costs. Whereas hospital and outpatient care are the major cost drivers.

Centers for Disease Control and Prevention (CDC) suggested that the Per capita national health expenditures in 2015 was amounted to be USD 9,990 and total national health expenditure was USD 3.2 trillion. It is also reported that out of total national health expenditures in the US, prescription drugs 10.1% share. According to the American Diabetes Association, nearly 30 million Americans are dealing with diabetes and every 21 seconds one person is diagnosed with diabetes.

Despite the great economic development in the Asia-Pacific region, some part of the region are facing inadequate health expenditure due to unequal distribution of resources. According to the findings published in Diabetes Research and Clinical Practice, the South East Asia Region was having lowest mean health expenditure per person with diabetes in 2014 which is approximately 87% lower than the world average.

Access this report at https://www.marketresearchfuture.com/reports/glucose-tolerance-test-market-4921 .

Diabetes is also found to be very prevalent in Middle East region. According to the International Diabetes Federation (IDF), Egypt is listed among the world top 10 countries with the higher number of diabetic patients in 2015. It is also estimated that the number of diabetic patients in the Middle East and North Africa (MENA) region will grow by 96% from year 2013 to 2035 i.e., from 34.6 million to 67.9 million. Despite the higher prevalence of diabetes in Egypt, the spending on diabetes among the Middle East and North Africa (MENA) region is the lowest i.e. USD 116 per patient per year, reported by IDF. This is much lower than the developed countries which ranges from USD2000 to USD7000 per patient per year

Segmentation

The global Glucose Tolerance Test market is segmented on the basis of products, indications, end user.

On the basis of the products, it is further segmented into intramedullary Blood glucose testing kit (Lancet, Meters, Test strips and others), Smart sensors and other.

On the basis of the indication, the market is segmented into Diabetes, Gestational diabetes, Insulin resistance, Reactive hypoglycemia.

On the basis of the end user, the market is segmented into Diagnostic Clinics, Hospitals, Home, and others.

On the basis of the end user, the market is segmented into hospitals & clinics, cancer research centers, and others.

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312

W: www.marketresearchfuture.com

sales@marketresearchfuture.com

This release was published on openPR.